

Horizons in Biomedicine

Hospital-Acquired Infections

Speaker Biographies

Duncan Purvis, Chief Scientist, Universal Sensors Ltd

Duncan finished his eclectic PhD at the Institute of Biotechnology in 1994 after serving 6 years prior to that as a research assistant in Royal Holloway College; working on evolutionary endocrinology; and a further 4 years within the Institute. He then joined Scientific Generics for 10 years as a technology consultant where he created solutions and inventions bridging many technology disciplines.

He started working with Sensortec to improve, develop and commercialise their basic concept technology early in 2000. Since that time the technology has evolved to become a commercially viable system that meets all the industries criteria. He joined Universal Sensors Ltd (subsidiary of Sensortec) as a director in September 2003 where he has led the technical development and commercialisation of this platform technology.

His expertise covers a wide range of disciplines bridging the interface of biology, physics and engineering. His interests go beyond the current leading edge of physics and biology.



Dr John Clarkson, CEO Atlas Genetics Ltd

John Clarkson has been in healthcare and diagnostics businesses for the past 13 years. He co-founded Molecular Sensors Limited in 1997, and then Molecular Sensing plc, where he was Technical Director.

Following the successful development of their DNA analysis system, he joined the US-based diagnostics company Osmetech plc as Instrument Systems Director when they acquired Molecular Sensing in 2004. John is now Chief Executive of Atlas Genetics Limited, which is developing rapid tests for infectious diseases such as HAIs, STDs, and specific high value veterinary applications. He has a PhD and over 20 years experience in genetics, molecular biology and microbiology.



Dr. David A Eustace, Product Development Manager, D3 Technologies Ltd

David worked as a postdoctoral research associate at the Dept. of Materials, Imperial College London from 2005-2008, working in the field of electron energy loss spectroscopy of a wide range of industrially relevant materials. This work, combined with an undergraduate degree in chemistry, has given David a wide breadth of experience in materials engineering and electronic structure.

He is now product development manager and project manager at D3 Technologies, where his background in spectroscopy and materials facilitates the development and advancement of Surface Enhance Raman Scattering into a wide range of new applications such as molecular



Dr Tim Gibson – Scensive Technologies Ltd.

Dr Tim Gibson received a BSc in 1975 in Medical Biochemistry from the University of Birmingham and a PhD in 'Stabilised, Enzyme Based Diagnostic Systems' in 1991 at the University of Leeds.

In 2004, Dr Gibson co-founded Scensive Technologies Ltd and is currently R&D Director. In 2005, he assisted in the purchase of Bloodhound Sensors Ltd. from the University of Leeds. Scensive is focussed on the use of chemical sensor technology for medical diagnosis, industrial odour monitoring systems and a multitude of other applications where smell and odour is important.

In 2007 a new spin-out was formed (ELISHA Systems Ltd) to exploit the results of the ELISHA project, which uses antibodies and other affinity reagents in labelless, rapid electrochemical sensor systems being developed for point-of-care devices.

